Follow
Fedor N Novikov
Fedor N Novikov
Pharmenterprises LLC
Verified email at pharmenterprises.ru - Homepage
Title
Cited by
Cited by
Year
Lead finder: An approach to improve accuracy of protein− ligand docking, binding energy estimation, and virtual screening
OV Stroganov, FN Novikov, VS Stroylov, V Kulkov, GG Chilov
Journal of Chemical Information and Modeling 48 (12), 2371-2385, 2008
2362008
Lung fibrosis after COVID-19: treatment prospects
E Bazdyrev, P Rusina, M Panova, F Novikov, I Grishagin, V Nebolsin
Pharmaceuticals 14 (8), 807, 2021
1822021
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
AA Mian, A Rafiei, I Haberbosch, A Zeifman, I Titov, V Stroylov, ...
Leukemia 29 (5), 1104-1114, 2015
662015
Lead Finder docking and virtual screening evaluation with Astex and DUD test sets
FN Novikov, VS Stroylov, AA Zeifman, OV Stroganov, V Kulkov, GG Chilov
Journal of computer-aided molecular design 26, 725-735, 2012
472012
Quantifying possible routes for SpnF-catalyzed formal Diels–Alder cycloaddition
MG Medvedev, AA Zeifman, FN Novikov, IS Bushmarinov, OV Stroganov, ...
Journal of the American Chemical Society 139 (11), 3942-3945, 2017
462017
Molecular docking: theoretical background, practical applications and perspectives
FN Novikov, GG Chilov
Mendeleev Communications 5 (19), 237-242, 2009
462009
Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin
M Sagnou, FN Novikov, ES Ivanova, P Alexiou, VS Stroylov, IY Titov, ...
European Journal of Medicinal Chemistry 198, 112331, 2020
412020
TSAR, a new graph–theoretical approach to computational modeling of protein side‐chain flexibility: Modeling of ionization properties of proteins
OV Stroganov, FN Novikov, AA Zeifman, VS Stroylov, GG Chilov
Proteins: Structure, Function, and Bioinformatics 79 (9), 2693-2710, 2011
352011
CSAR scoring challenge reveals the need for new concepts in estimating protein–ligand binding affinity
FN Novikov, AA Zeifman, OV Stroganov, VS Stroylov, V Kulkov, GG Chilov
Journal of chemical information and modeling 51 (9), 2090-2096, 2011
322011
PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
ES Ivanova, VV Tatarskiy, MA Yastrebova, AI Khamidullina, AV Shunaev, ...
International Journal of Oncology 55 (1), 289-297, 2019
262019
Exhaustive conformational search for transition states: the case of catechol O-methyltransferase active site
MG Medvedev, MV Panova, GG Chilov, IS Bushmarinov, FN Novikov, ...
Mendeleev Communications 27 (3), 224-227, 2017
262017
Improving performance of docking-based virtual screening by structural filtration
FN Novikov, VS Stroylov, OV Stroganov, GG Chilov
Journal of molecular modeling 16, 1223-1230, 2010
242010
Molecular basis of COVID-19 pathogenesis
FN Novikov, VS Stroylov, IV Svitanko, VE Nebolsin
Russian Chemical Reviews 89 (8), 858, 2020
232020
Developing novel approaches to improve binding energy estimation and virtual screening: a PARP case study
FN Novikov, VS Stroylov, OV Stroganov, V Kulkov, GG Chilov
Journal of molecular modeling 15, 1337-1347, 2009
232009
PF-114: a 4th generation tyrosine kinase-inhibitor for chronic phase chronic myeloid leukaemia including BCRABL1T315I
AG Turkina, O Vinogradova, E Lomaia, E Shatokhina, OA Shukhov, ...
Blood 134, 1638, 2019
212019
Rational design and synthesis of new PARP1 inhibitors
LV Romashov, AA Zeifman, AL Zakharenko, FN Novikov, VS Stroilov, ...
Mendeleev Communications 22 (1), 15-17, 2012
192012
Novel Antitumor L‐Arabinose Derivative of Indolocarbazole with High Affinity to DNA
DN Kaluzhny, VV Tatarskiy Jr, LG Dezhenkova, IL Plikhtyak, TD Miniker, ...
ChemMedChem: Chemistry Enabling Drug Discovery 4 (10), 1641-1648, 2009
192009
Molecular modeling of different substrate‐binding modes and their role in penicillin acylase catalysis
FN Novikov, OV Stroganov, IG Khaliullin, NV Panin, IV Shapovalova, ...
The FEBS Journal 280 (1), 115-126, 2013
182013
Phase-1 study of PF-114 mesylate in CML failing prior tyrosine kinase-inhibitor therapy
AG Turkina, O Vinogradova, E Lomaia, E Shatokhina, O Shukhov, ...
Blood 132, 790, 2018
172018
The hidden pandemic of COVID-19-induced organizing pneumonia
E Bazdyrev, M Panova, V Zherebtsova, A Burdenkova, I Grishagin, ...
Pharmaceuticals 15 (12), 1574, 2022
152022
The system can't perform the operation now. Try again later.
Articles 1–20